Autoimmune hemolytic anemia |
Autoimmune hemolytic anemia On the Web |
---|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
Risk calculators and risk factors for Autoimmune hemolytic anemia |
For the WikiDoc page for this topic, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani
Autoimmune hemolytic anemia occurs when antibodies form against the body's own red blood cells and destroy them. This happens because the immune system mistakenly recognizes these blood cells as foreign.
You may not have symptoms if the anemia is mild. If the problem develops slowly, symptoms that may occur first include:
If the anemia gets worse, symptoms may include:
Possible causes include:
When antibodies form against red blood cells for no reason, the condition is called idiopathic autoimmune hemolytic anemia.
The antibodies may also be caused by:
Risk factors are related to the causes.
Call your healthcare provider if you have unexplained fatigue or chest pain, or signs of infection.
The first treatment tried is usually a steroid medication, such as prednisone. If steroid medications do not improve the condition, treatment with intravenous immunoglobulin (IVIG) or removal of the spleen (splenectomy) may be considered.
You may receive treatment to suppress your immune system if you do not respond to steroids and splenectomy. Medications such as azathioprine (Imuran), cyclophosphamide (Cytoxan), and rituximab (Rituxan) have been used.
Blood transfusions are given with caution because the blood may not be compatible and it may cause more red blood cell destruction.
Directions to Hospitals Treating Thrombocytopenia
The disease may start quickly and be very serious, or it may stay mild and not need special treatment.
In most people, steroids or splenectomy can totally or partially control anemia.
Severe anemia rarely leads to death. Severe infection may occur as a complication of treatment with steroids, other medicines that suppress the immune system, or splenectomy. These treatments impair the body's ability to fight infection.
Screening for antibodies in donated blood and in the recipient may prevent hemolytic anemia related to blood transfusions.